Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2019 Nov;187(3):277-285.
doi: 10.1111/bjh.16167. Epub 2019 Aug 20.

How we manage Bing-Neel syndrome

Jorge J Castillo  1 , Steven P Treon  1
Affiliations
Review

How we manage Bing-Neel syndrome

Jorge J Castillo et al. Br J Haematol. 2019 Nov.

Abstract

Bing-Neel syndrome (BNS) is an uncommon presentation of Waldenström macroglobulinaemia (WM), seen during the course of the disease in about 1% of patients. BNS occurs when WM cells gain access to the central nervous system (CNS) causing neurological deficits. The diagnosis of BNS is suggested by the presence of radiological abnormalities, such as leptomeningeal enhancement on magnetic resonance imaging and confirmed by the presence of clonal lymphoplasmacytic cells and MYD88 L265P in the cerebrospinal fluid. The treatment of BNS requires agents with good penetration into the CNS, such as fludarabine, methotrexate and cytarabine. The novel Bruton Tyrosine Kinase inhibitor ibrutinib has shown CNS-penetrating properties, and recent data suggest a therapeutic role in BNS. In this review, we will discuss the clinical and pathological features, diagnostic criteria, treatment options and outcomes of patients with BNS.

Keywords: Bing Neel syndrome; Waldenstrom Macroglobulinaemia; ibrutinib.

PubMed Disclaimer

References

    1. Ayanambakkam, A., Ibrahimi, S., Bilal, K. & Cherry, M.A. (2018) Extranodal marginal zone lymphoma of the central nervous system. Clinical Lymphoma Myeloma and Leukemia, 18, 34-37.e8.
    1. Badros, A., Singh, Z., Dhakal, B., Kwok, Y., MacLaren, A., Richardson, P., Trikha, M. & Hari, P. (2017) Marizomib for central nervous system-multiple myeloma. British Journal of Haematology, 177, 221-225.
    1. Bernard, S., Goldwirt, L., Amorim, S., Brice, P., Briere, J., de Kerviler, E., Mourah, S., Sauvageon, H. & Thieblemont, C. (2015) Activity of ibrutinib in mantle cell lymphoma patients with central nervous system relapse. Blood, 126, 1695-1698.
    1. Bing, J. & Neel, A. (1936) Two cases of hyperglobulinemia with affection of the central nervous system on a toxi-infectious basis. Acta Medica Scandinavica, LXXXVIII, 492-506.
    1. Boudin, L., Patient, M., Romeo, E., Blade, J.S. & de Jaureguiberry, J.P. (2018) Efficacy of ibrutinib as first-line treatment of tumoral Bing-Neel syndrome. Leukaemia & Lymphoma, 59, 2746-2748.

MeSH terms

LinkOut - more resources